Uncategorized

This will also be the first instance since RVNL’s listing that the stock would have declined for five months in a row.

The Founder and Chief Investment Officer of Shikhara Investment likes IT, pharma, and healthcare sectors, and has reduced exposure to costly domestic cyclical stocks.

IREDA had approved raising funds to the tune of ₹4,500 crore last year, and the government is likely to dilute up to 7% stake of its stake in the company through this QIP.

All 10 analysts who have coverage on Piramal Pharma, have a “buy” rating on the stock. JM Financial has the highest price target on the stock at ₹340.

Brokerage firm Kotak Institutional Equities has cut its price target to ₹1,330 from ₹1,475 earlier, while Ambit has a target of ₹1,037 on the stock.

With valuations nearing all-time highs, BSE’s pricing appears aligned with global peers, leaving the risk-reward outlook largely balanced, the brokerage said.

Last week, brokerage firm Goldman Sachs had downgraded IndusInd Bank’s shares to “neutral” from its earlier rating of “buy” and also cut its price target to ₹1,090 from over ₹1,300 earlier.

On Monday, market tech analyst Mitessh Thakkar and F&O analyst Chandan Taparia recommended these stocks for the short term.

The IPO was subscribed a solid 183.18 times at close. The category for the QIBs was booked 331.60 times, while the portion for the NIIs was subscribed 268.50 times. The quota for retail investors was booked 64.99 times during the…